Protalix BioTherapeutics
PLX
36 hedge funds and large institutions have $3.47M invested in Protalix BioTherapeutics in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 5 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
0.01% less ownership
Funds ownership: 0.77% → 0.76% (-0.01%)
5% less funds holding
Funds holding: 38 → 36 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
58% less capital invested
Capital invested by funds: $8.2M → $3.47M (-$4.73M)
73% less call options, than puts
Call options by funds: $22K | Put options by funds: $81K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$207K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$59K |
| 3 |
VF
Virtu Financial
New York
|
+$13.4K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$10.8K |
| 5 |
Jane Street
New York
|
+$10.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$221K |
| 2 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$156K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$47.5K |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$33.6K |
| 5 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$22K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Simplex Trading
Chicago,
Illinois
| $6K | +$8.81K | +1,855 | +824% |
|
|
FDCDDQ
27
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $3.42K | – | – | – |
|
|
CB
28
Commerce Bank
Kansas City,
Missouri
| $3K | – | – | – |
|
29
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | – | – | – |
|
|
KPW
30
Kore Private Wealth
New York
| $2K | +$2.38K | +500 | New |
|
|
EMG
31
ETF Managers Group
Summit,
New Jersey
| – | -$221K | -33,152 | Closed |
|
|
WAM
32
Wolverine Asset Management
Chicago,
Illinois
| – | -$156K | -21,494 | Closed |
|
|
33
Wells Fargo
San Francisco,
California
| – | -$47.5K | -10,000 | -99% |
|
|
LTFS
34
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | -$22K | -3,000 | Closed |
|
35
Bank of America
Charlotte,
North Carolina
| – | -$8.69K | -1,829 | -98% |
|
|
SPIA
36
Steward Partners Investment Advisory
New York
| – | -$1K | -200 | Closed |
|
|
ASN
37
Advisory Services Network
Atlanta,
Georgia
| – | -$1K | -100 | Closed |
|
|
AIA
38
Alera Investment Advisors
Deerfield,
Illinois
| – | +$475 | +100 | New |
|
39
JP Morgan Chase
New York
| – | +$475 | +100 | New |
|
PLX Hedge Fund Activity: Q4 2018 in Review
36 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q4 2018, worth a combined $3.47M — down 58% from $8.2M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of PLX and 3 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 8 added.
The largest buyer was Renaissance Technologies, adding an estimated $207K. The largest seller was ETF Managers Group, exiting entirely with an estimated $221K sold.
- 36 institutional investors held Protalix BioTherapeutics (PLX) as of Q4 2018, down from 38 in Q3 2018.
- Funds reported $3.47M of Protalix BioTherapeutics stock for Q4 2018, down 58% quarter-over-quarter.
- 3 funds opened new Protalix BioTherapeutics positions in Q4 2018 and 5 closed out, a net change of -2 holders.
- The largest Protalix BioTherapeutics buyer in Q4 2018 was Renaissance Technologies, an estimated $207K added.
- The largest Protalix BioTherapeutics seller in Q4 2018 was ETF Managers Group, an estimated $221K sold.
Based on aggregated 13F filings for Q4 2018.